

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Ravulizumab for treating atypical haemolytic uraemic syndrome (aHUS) ID1530

Draft stakeholder list of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> • Alexion Pharma UK (ravulizumab) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Action for Sick Children • Answers for aHUS • Contact a Family • Findacure • Genetic Alliance UK • Kidney Care UK • Kidney Research UK • Kids Kidney Research • Muslim Council of Britain • National Children's Bureau • National Kidney Federation • South Asian Health Foundation • Specialised Healthcare Alliance • Thrombosis UK <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • Association of Renal Industries • Association of Renal Technologists • Association of Surgeons of Great Britain and Ireland • British Association for Paediatric Nephrology • British Association of Urological Nurses • British Association of Urological Surgeons • British Committee for Standards in Haematology • British Geriatric Society 	<p><u>General</u></p> <ul style="list-style-type: none"> • All Wales Therapeutic and Toxicology Centre • Allied Health Professionals Federation • Association of Renal Industries • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Hospital Information Services - Jehovah's Witnesses • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Confederation • Scottish Medicines Consortium • Welsh Government • Welsh Health Specialised Services Committee • Welsh Kidney Patients Association • Welsh Urological Society <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> • None <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Cochrane Kidney & Transplant • Genomics England

Draft stakeholder list for the appraisal of ravulizumab for treating atypical haemolytic uraemic syndrome (aHUS) ID1530

Issue Date: July 2020

© National Institute for Health and Care Excellence 2020. All rights reserved

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • British Renal Society • British Society for Haematology • British Society for Human Genetics • British Transplantation Society • NHS Blood and Transplant • Rare Renal • Renal Association • Royal College of Anaesthetists • Royal College of General Practitioners • Royal College of Nursing • Royal College of Paediatrics & Child Health • Royal College of Pathologists • Royal College of Physicians • Royal College of Surgeons • Royal Pharmaceutical Society • Royal Society of Medicine • Society for DGH Nephrologists • UK Clinical Pharmacy Association • UK Forum on Haemoglobin Disorders • UK National Screening Committee • UK Primary Immunodeficiency Network • UK Renal Pharmacy Group • Urology Foundation <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health and Social Care • National Renal Complement Therapeutics Centre • NHS England 	<ul style="list-style-type: none"> • MRC Clinical Trials Unit • National Institute for Health Research <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> • Public Health England • Public Health Wales

NICE is committed to promoting equality and eliminating unlawful discrimination.

Please let us know if we have missed any important organisations from the lists contained within the provisional stakeholder list and which organisations we should include who have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTTEES AND COMMENTATORS

Draft stakeholder list for the appraisal of ravulizumab for treating atypical haemolytic uraemic syndrome (aHUS) ID1530

Issue Date: July 2020

© National Institute for Health and Care Excellence 2020. All rights reserved

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Document (FAD).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Document (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company commentators are invited to nominate clinical specialists or patient experts.

¹ Non-company consultees are invited to submit statements relevant to the group they are representing.